CytomX is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics.
CytomX’s Probody™ Platform represents a transformational drug discovery and development approach for antibodies, enabling improved specificity, increased efficacy and decreased toxicity. The Company was founded in Santa Barbara with technology licensed from University of California, Santa Barbara. CytomX moved to the San Francisco Bay Area in 2011, after raising its first round of venture capital.
CytomX’s novel platform is driving the development of Probodies, breakthrough antibody therapeutics that achieve unprecedented levels of diseased tissue-specific targeting. Probodies are designed to bind to antigens only in diseased tissue and not in healthy tissue, and therefore have the potential to open up new target space and expand the therapeutic index of current antibody therapies.